Amoxapine (Asendin) is a hybrid drug: chemically it is a derivative of the antipsychotic loxapine, and pharmacologically it does both jobs at once, blocking the norepinephrine pump like a tricyclic antidepressant and blocking dopamine D2 receptors like an antipsychotic. That dual action made it briefly attractive in the early 1980s for depressed patients with psychotic features. The downside is that it carries the entire side-effect package of antipsychotics, including risk of tardive dyskinesia (a movement disorder that can become permanent) and neuroleptic malignant syndrome (a rare but life-threatening reaction). Those risks have largely pushed it out of routine use in favor of separate SSRI and antipsychotic combinations. Not stocked by Kodiac. This monograph is provided for research and educational reference.
Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.
Dibenzoxazepine tricyclic antidepressant with dopamine D2 receptor antagonism and 5-HT2/5-HT6 serotonergic activity
A second-generation tricyclic antidepressant derived from the antipsychotic loxapine, distinguished from classical tricyclics by potent dopamine D2 receptor antagonism through its 7-hydroxy metabolite, sub-nanomolar 5-HT2A affinity, rapid clinical onset, and emerging preclinical interest as a 5-HT6-mediated reducer of amyloid-beta generation.
Abstract
Amoxapine is a dibenzoxazepine tricyclic antidepressant approved by the United States Food and Drug Administration in 1980 for the treatment of major depressive disorder. Structurally, it is the N-demethylated metabolite of the antipsychotic loxapine and retains substantial dopamine D2 receptor antagonist activity, principally through its major active metabolite 7-hydroxyamoxapine, a property that distinguishes it from all other marketed tricyclic antidepressants and positions it pharmacologically as a combined antidepressant-antipsychotic agent. The compound inhibits norepinephrine reuptake with high potency (Ki approximately 16 nM at the norepinephrine transporter) and serotonin reuptake with moderate potency (Ki approximately 58 nM at the serotonin transporter), while exhibiting sub-nanomolar affinity for the 5-HT2A receptor (Ki approximately 0.5 nM) and low-nanomolar affinity for 5-HT2C, dopamine D2, D3, D4, and histamine H1 receptors. The receptor binding profile is among the broadest of the tricyclic class and approximates that of certain atypical antipsychotics.
Pharmacokinetics are characterized by rapid oral absorption (time to peak approximately 1 to 2 hours), oral bioavailability exceeding 60 percent, plasma protein binding of approximately 90 percent, and hepatic metabolism predominantly via CYP2D6 to two pharmacologically active metabolites: 7-hydroxyamoxapine (a potent dopamine antagonist with a half-life of approximately 6.5 hours) and 8-hydroxyamoxapine (a serotonin-norepinephrine reuptake inhibitor with a half-life of approximately 30 hours). The extended half-life of the 8-hydroxy metabolite dominates the steady-state pharmacokinetic profile and contributes to once-daily dosing feasibility. CYP2D6 poor metabolizers exhibit elevated plasma concentrations of the parent compound and altered metabolite ratios.
Clinical efficacy in major depressive disorder is well established across multiple randomized controlled trials, with antidepressant potency comparable to imipramine and amitriptyline. A distinguishing clinical feature is the reportedly rapid onset of antidepressant action, with therapeutic effects observed in some patients within four to seven days, substantially faster than the two-to-four-week latency typical of other tricyclic agents. The dopaminergic antagonism through 7-hydroxyamoxapine confers neuroleptic-like properties that have supported off-label use in psychotic depression and as adjunctive antipsychotic therapy, but also introduces adverse event risks characteristic of antipsychotic agents, including extrapyramidal symptoms, tardive dyskinesia, and neuroleptic malignant syndrome.
Emerging preclinical research has identified amoxapine as a potent 5-HT6 receptor antagonist capable of reducing amyloid-beta generation through HTR6-mediated modulation of beta-secretase (BACE1) activity via beta-arrestin2 and CDK5 signaling pathways (Li et al., 2017). At 10 micromolar concentration in human neuronal cell lines, amoxapine reduced secreted amyloid-beta by approximately 37 percent without affecting cell viability, positioning the compound as a candidate for drug repurposing investigation in Alzheimer disease research. This monograph reviews the chemistry, synthesis, and structural pharmacology of amoxapine; the multi-receptor mechanism of action; the comprehensive pharmacokinetic record including CYP2D6 polymorphism; the clinical evidence base in depression and psychotic depression; the reconstitution, sourcing, and handling considerations for laboratory work; the stack-interaction and safety considerations including the unique antipsychotic adverse-event signal; and a comparative assessment of five alternative antidepressant compounds against amoxapine on five competency standards.
Read the full monograph
The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.
FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.